Current Status of Dengue Therapeutics Research and Development

@article{Low2017CurrentSO,
  title={Current Status of Dengue Therapeutics Research and Development},
  author={Jenny Guek-Hong Low and Eng Eong Ooi and Subhash G. Vasudevan},
  journal={The Journal of Infectious Diseases},
  year={2017},
  volume={215},
  pages={S96 - S102}
}
Abstract Dengue is a significant global health problem. Even though a vaccine against dengue is now available, which is a notable achievement, its long-term protective efficacy against each of the 4 dengue virus serotypes remains to be definitively determined. Consequently, drugs directed at the viral targets or critical host mechanisms that can be used safely as prophylaxis or treatment to effectively ameliorate disease or reduce disease severity and fatalities are still needed to reduce the… Expand

Figures, Tables, and Topics from this paper

Dengue Antiviral Development: A Continuing Journey.
TLDR
In recent years, efforts to develop dengue therapeutics have focused on both repurposing approved drugs as well as discovery of new chemical entities that act via virus or host targeted mechanisms. Expand
Dengue
TLDR
A crucial assessment of vector control tools should guide a research agenda for determining the most effective interventions, and how to best combine state-of-the-art vector control with vaccination. Expand
Dengue: A Minireview
TLDR
This work reviews DENV biology, epidemiology, transmission dynamics including circulating serotypes and genotypes, the immune response, the pathogenesis of the disease as well as updated diagnostic methods, treatments, vector control and vaccine developments. Expand
Lessons Learned and Recent Advances in Dengue Research
Dengue is the most important arbovirus, many research have contributed to the diagnosis, management, prevention and control of this disease, which will be described in this chapter, for example: theExpand
Current Trends and Limitations in Dengue Antiviral Research
TLDR
Increase in structural insights into the dengue NS5 protein will accelerate drug discovery efforts focused on NS5 as an antiviral target, which is the largest and most conserved nonstructural protein encoded by flaviviruses. Expand
A Multi-perspective Review of Dengue Research.
TLDR
The importance of Natural chemical moieties like methionine-proline anilides, tetrapeptide aldehyde via Structure Activity Relationship studies and the drug candidates currently in the clinical trials that have the potential to solve this issue are explained. Expand
Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication
TLDR
This review elaborate the ribozymes, RNA interference, CRISPR, aptamer and morpholino strategies for the inhibition of DENV replication and discuss the challenges involved in utilizing such approaches. Expand
A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.
TLDR
A highly potent dengue virus inhibitor (JNJ-A07) that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes, thus revealing a previously undescribed mechanism of antiviral action. Expand
Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate
TLDR
The pathogenic roles of DENV NS1 in hemorrhage and vascular leakage are reviewed, and the possibility of using NS1 as a therapeutic target and vaccine candidate is discussed. Expand
Bioethics of establishing a CHIM model for dengue vaccine development.
  • Anuradha Rose, Amrita Sekhar
  • Medicine
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2019
INTRODUCTION Controlled human infection models (CHIM) have been used in vaccine development to up-select and down-select potential vaccine candidates and to provide proof of vaccine efficacy, andExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 90 REFERENCES
Dengue Human Infection Models Supporting Drug Development
TLDR
The merits of a dengue human infection model (DHIM) for drug development could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with d Dengue in an endemic country. Expand
Report of an NIAID workshop on dengue animal models.
TLDR
This report summarizes the main discussions and recommendations that resulted from the meeting to consider the current state-of-the-art developments in animal models for dengue and discuss strategies to accelerate progress in this field. Expand
Therapeutic antibodies as a treatment option for dengue fever
TLDR
The strategies and technologies that can be adopted to develop antibodies for therapeutic applications are reviewed and the mechanism of antibody neutralization in the cells targeted by DENV that express Fc gamma receptor is discussed. Expand
Dengue human infection model performance parameters.
  • T. Endy
  • Biology, Medicine
  • The Journal of infectious diseases
  • 2014
TLDR
A dengue human infection model (DHIM) will be an essential tool in developing potential d Dengue vaccines or antivirals and the potential performance parameters needed for a DHIM to support vaccine or antiviral candidates are discussed. Expand
New insights into the immunopathology and control of dengue virus infection
TLDR
Recent advances in the understanding of immunopathology, vaccine development and human monoclonal antibodies produced against dengue virus are outlined. Expand
Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions
TLDR
This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013. Expand
The Animal Models for Dengue Virus Infection
TLDR
The development of small animal models such as mice for dengue virus infections is reviewed and the mechanisms involved in the pathogenesis of DHF/DSS remain poorly understood. Expand
A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein
TLDR
A novel small-molecule compound, ST-148, is described that is a potent inhibitor of all four serotypes of DENV in vitro and appears to interact with the DENV C protein and inhibits a distinct step of the viral replication cycle. Expand
Experimental therapies for yellow fever.
TLDR
Current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection, are reviewed. Expand
Characterization of the Mode of Action of a Potent Dengue Virus Capsid Inhibitor
TLDR
The mode of action of ST-148, a small-molecule capsid inhibitor with potent antiviral activity against all DV serotypes is investigated by using a combination of biochemical, virological, and imaging-based techniques to demonstrate that it stabilizes capsid protein self-interaction. Expand
...
1
2
3
4
5
...